Feb. 25, 2025— GE HealthCare has delivered the first patient doses of Flyrcado (flurpiridaz F 18) injection, a unit dose positron emission tomography myocardial perfusion imaging (PET MPI) agent for detecting coronary artery disease (CAD), at early adopter imaging centers in the US. This  follows the recent FDA approval of Flyrcado, which is indicated for patients with known or suspected CAD, and delivers higher diagnostic efficacy compared to single-photon emission computed tomography (SPECT) MPI..

March 3, 2025 — Eko Health has published a peer-reviewed study in JACC Advances evaluating its 

Feb. 25, 2025 — Heartflow, Inc., a provider of AI technology for coronary artery disease (CAD) management, recently introduced its new brand identity reflecting its focus on delivering clarity, precision and confidence in the prevention, diagnosis and treatment of CAD.


Imagine a future where a silent, undetected heart condition is caught before it turns into a life-threatening event — a future where artificial intelligence (AI) -powered insights alert clinicians to warning signs long before symptoms appear. That future isn’t decades away. It is already here.

Feb. 17, 2025 — The International Consortium for Health Outcomes Measurement (ICHOM) has developed a globally inclusive standard dataset of 16 patient-centered outcome measures for people with heart valve disease, regardless of treatment (surgical or transcatheter procedure), according to a new report published in the American Heart Association’s journal Circulation: Cardiovascular Quality & Outcomes.

Feb. 11, 2025  — UltraSight, a company committed to enhancing the efficiency and productivity of cardiac ultrasound, recently announced support from Bristol Myers Squibb (BMS) for a study that aims to improve access to echocardiographic assessments for patients with obstructive hypertrophic cardiomyopathy (oHCM).

Cardiac ultrasound is routinely used as an essential tool in the diagnosis and management of oHCM.

Feb. 13, 2025 — Research from Cedars-Sinai investigators and collaborators at other leading medical institutions is helping to provide more treatment options to people living with tricuspid valve disease..

Feb. 10, 2025 — A generous gift of $5 million from Lorraine and Bill Dodero will establish the Lorraine and Bill Dodero Limb Preservation Center at University Hospitals Harrington Heart & Vascular Institute in Cleveland, Ohio. Led by Mehdi Shishehbor DO, MPH, PhD, interventional cardiologist and a pioneer in the field of limb preservation, the Dodero Center will revolutionize care for patients at risk of losing a leg due to peripheral artery disease and diabetes.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now